Fee-for-service reimbursement has been blamed for excessive utilization and health spending, and so it follows that a number of alternative methods are being created and put into use. The Network for Excellence in Health Innovation has produced a brief examining the impact of these new reimbursement methodologies on innovation. (NEHI Brief) Bundled payments typically pay a set fee for an episode care. They obviously work best for a clearly defined episode, such as a surgery. Other methods, such as value-based purchasing, may look at the larger scope of care for a patient and adjust payment depending on outcomes and cost. And capitation typically gives a provider a set monthly fee to be responsible for all the health needs of a patient. Bundling or episode of care payments are designed to limit spending by defining what appropriate care and cost for that care should be. They are by definition an average, although some may be risk-adjusted for a patient. The brief addresses the often-expressed concern that these bundled payments may focus providers too much on saving money and therefore lead to avoidance of care that could help a patient, and may thwart the development and adoption of new technologies and procedures that could provide better outcomes for patients. For some of its reimbursement methods, CMS has addressed these concerns by providing add-on or pass-through payments for certain new products. While the concern may be legitimate, one ongoing problem in our health system is that many new “innovative” products may have a high price tag but do little to improve quality. Me-too brand name drugs are an obvious example, along with minor modifications, such as extended release, to extend patent protection for a drug. Medical devices face similar concerns, with many new products providing only incremental benefit at a large price. Robotic surgery comes to mind as an “innovation” that has raised costs with research increasingly suggesting that outcomes no only aren’t better, but may be worse. In general, payers should not have to pay more for an innovative product or procedure than they would for the usual care unless and until the new product or procedure has been clearly demonstrated to significantly improve meaningful patient outcomes. At that point, its cost can be negotiated, but cost should not inhibit the delivery of the best possible care to patients.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
What do you get when you combine a company with a commodity business model, that out of desperation massively overpays for another company that has a commodity business model? $10...
July 27, 2022
The “stupid” model for health care venture capital investing is alive and well. Everside health, which operates primary care clinics and has grown by acquiring other failing health care businesses,...
July 26, 2022
Apparently not even a cute name can save you if you have a stupid business. I constantly bemoan the mis-application of capital and health care is Exhibit A. Olive, another...
July 26, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace